



FINANCIAL TEAR SHEET


COMPANY OVERVIEW

Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically defined patient populations. Because gene expression is fundamental to the function of all cells, the Company's gene control platform has broad potential to achieve profound and durable benefit across a range of diseases. Syros is focused on cancer and immune-mediated diseases and is advancing a growing pipeline, including its lead drug candidates SY-1425, a selective RAR α agonist for genomically defined subsets of patients identified by its platform, for a range of cancers including acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor for a range of blood cancers and solid tumors. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located in Cambridge, Mass.

STOCK INFORMATION

| NDAQ (Common) | |
|--------------------|--------------------|
| Exchange | NASDAQ (US Dollar) |
| Price | \$67.58 |
| Change (%) | ▼ 0.61 (0.89%) |
| Volume | 561,729 |
| 52 Week Low | \$61.19 |
| Market Cap | \$11,263,520,483 |
| Rolling EPS | 0.82 |
| PE Ratio | 82.6766 |
| Shares Outstanding | 165,178,479 |

Data as of 05/26/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

RECENT PRESS RELEASES

| Date | Title |
|----------|---|
| 05/18/17 | Syros to Present on SY-1425 in Combination with Standard-of-Care and Targeted Therapies in Genomically Defined Subsets of AML and MDS Patients |
| 05/15/17 | Syros Reports First Quarter 2017 Financial Results and Highlights Accomplishments and Upcoming Milestones |
| 05/15/17 | Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-1365, Its First-in-Class Selective CDK7 Inhibitor, in Patients with Advanced Solid Tumors |

SEC FILINGS

| Filing Date | Form |
|-------------|--------|
| 05/25/17 | EFFECT |
| 05/25/17 | 424B3 |
| 05/15/17 | S-1 |
| 05/15/17 | 10-Q |

UPCOMING EVENTS

There are currently no events scheduled.

PRIMARY IR CONTACT

Hannah Deresiewicz
Stern Investor Relations
E-mail: hannahd@sternir.com